Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
Type:
Grant
Filed:
October 13, 2022
Date of Patent:
May 7, 2024
Assignee:
Genzyme Corporation
Inventors:
Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
Abstract: The present invention provides a method for producing megakaryocytes that have an increased capacity to produce platelets, the method comprising a step of culturing, under conditions that cause the death of cells that do not express a gene that is specifically expressed by megakaryocytes, cells that have the capacity to differentiate into megakaryocytes.
Type:
Grant
Filed:
March 22, 2021
Date of Patent:
May 7, 2024
Assignees:
Megakaryon Corporation, Kyoto University
Inventors:
Takeaki Dohda, Sachiko Kobayashi, Koji Eto, Hiroshi Endo, Sou Nakamura
Abstract: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5?ITR-B1-BA-B2-BX-BB-BY-B3-3?ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
Type:
Grant
Filed:
December 23, 2020
Date of Patent:
March 26, 2024
Assignee:
AKAMIS BIO LIMITED
Inventors:
Brian Robert Champion, Alice Claire Noel Brown, Kerry David Fisher, Tamara Nicolson
Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.
Type:
Grant
Filed:
March 14, 2018
Date of Patent:
March 26, 2024
Assignee:
Seattle Children's Hospital
Inventors:
David J. Rawlings, Richard James, Shaun W. Jackson, Iram Khan, King Hung, Andrew M. Scharenberg
Abstract: The present inventions relates to an isolated nucleic acid molecule comprising a nucleotide sequence coding for a depolarizing light-gated ion channel functionally linked to a promoter leading to the specific expression of said depolarizing light-gated ion channel in a retinal photoreceptor, or the nucleotide sequence complementary to said nucleotide sequence, for use in treating or ameliorating blindness. The present invention also relates to methods of using such nucleic acid molecules in the treatment of blindness.
Type:
Grant
Filed:
October 30, 2020
Date of Patent:
March 19, 2024
Assignee:
FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH
Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.
Type:
Grant
Filed:
November 10, 2022
Date of Patent:
February 27, 2024
Assignee:
Genzyme Corporation
Inventors:
Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng
Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.
Type:
Grant
Filed:
October 19, 2017
Date of Patent:
January 16, 2024
Assignee:
CELLECTIS
Inventors:
Brian Busser, Philippe Duchateau, Alexandre Juillerat, Laurent Poirot, Julien Valton
Abstract: This invention relates to vectors for delivery of human leukocyte antigen G to the eye and/or to cornea explants and methods of using the same for treatment and/or prevention of corneal transplant rejection and other disorders associated with an immune response and/or vascularization.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
January 9, 2024
Assignees:
The University of North Carolina at Chapel Hill, North Carolina State University
Inventors:
Matthew Louis Hirsch, Brian Christopher Gilger
Abstract: Bacillus agaradhaerens strain WDG185 expresses an inulosucrase that efficiently synthesizes a broad range of IOS with a GF range of GF3-GF30. The isolated and/or purified inulosucrase, recombinantly engineered variants thereof, active fragments thereof, synthetic nucleic acids encoding the inulosucrase, its variants, or its active fragments, host cells comprising the synthetic nucleic acids, and compositions comprising the inulosucrase are provided. Methods of using the compositions include the manufacture of inulooligosaccharides.
Type:
Grant
Filed:
September 17, 2020
Date of Patent:
January 2, 2024
Assignee:
Danisco US Inc.
Inventors:
Slavko Kralj, Marc Kolkman, Chris Leeflang, Johannes G. De Nobel, Arjen Hoekstra, Veli Alkan
Abstract: Human Neural precursor cells (hNPCs)/cell lines derived from human pluripotent stem cells have been stably transduced with inducible lentiviral constructs for knockdown of STIM1 thereby changing their gene expression. The said Human Neural precursor cells (hNPCs)/cell lines has selectively inducible knockdown of STIM1 via stable transduction of lentiviral shRNA vector followed by Doxycycline treatment. Human Neural precursor cells (hNPCs)/cell lines with stable knockdown STIM1 exhibits attenuated SOCE with downregulation of genes associated with cell proliferation and upregulation of genes for neural differentiation.
Type:
Grant
Filed:
April 17, 2019
Date of Patent:
December 26, 2023
Assignee:
NATIONAL CENTRE FOR BIOLOGICAL SCIENCES
Inventors:
Renjitha Gopurappilly, Gaiti Hasan, Bipan Kumar Deb
Abstract: Provided is a method for preventing or treating a metabolic disorder, including administering to a subject a therapeutically effective amount of TRABID protein or a functionally related variant thereof, or a nucleic acid encoding TRABID protein or a functionally related variant thereof. Also provided is a method for reducing fat accumulation through TRABID-induced deubiquitination to promote autophagy activity and lipid metabolism.
Type:
Grant
Filed:
December 2, 2021
Date of Patent:
November 14, 2023
Assignees:
Academia Sinica, National Yang Ming Chiao Tung University
Abstract: Methods of, treatments using, and devices for restoring the regenerative capability for mesenchymal stem cells and isolating and expanding a small subpopulation of less defective mesenchymal stem cells from the bone marrow stromal cells of people with decreased quality and/or quantity of mesenchymal stem cells, such as elderly people.
Type:
Grant
Filed:
November 4, 2016
Date of Patent:
October 31, 2023
Assignee:
The Board of Regents of The University of Texas System
Abstract: Aspects of the disclosure relate to methods and compositions for treating pancreatic cancer (e.g., islet cell tumors). In some aspects, adeno-associated virus (AAV) may be used to deliver an interfering RNA that targets thymidylate synthase (TS).
Type:
Grant
Filed:
November 3, 2017
Date of Patent:
October 10, 2023
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: A problem of this invention it to provide a method for differentiate a primordial germ cell into a functional GV stage oocyte by in vitro culture. This invention relates to a method for differentiating a primordial germ cell into a functional GV stage oocyte by in vitro culture, comprising: (a) a step of producing a secondary follicle by culturing the primordial germ cell and supporting cells adjacent to the primordial germ cells under conditions that eliminate the effects of estrogen or a factor having a similar function to estrogen; (b) a step of partially dissociating cells between a granulosa cell layer and a thecal cell layer, wherein an oocyte, the granulosa cell layer, and the thecal cell layer constitute the produced secondary follicle; and (c) a step of differentiating the oocyte into a functional GV stage oocyte by culturing the oocyte, the granulosa cell layer, and the thecal cell layer that constitute the secondary follicle in a medium containing a high-molecular-weight compound.
Type:
Grant
Filed:
September 16, 2016
Date of Patent:
October 3, 2023
Assignees:
NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, TOKYO UNIVERSITY OF AGRICULTURE EDUCATIONAL CORPORATED
Abstract: The invention relates to an ex vivo generated population of tissue-specific anti-inflammatory macrophages and methods of making and using such macrophages.
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
September 19, 2023
Assignee:
Wisconsin Alumi Research Foundation
Inventors:
Peiman Hematti, Eric G. Schmuck, John A. Kink, Amish N. Raval
Abstract: The present invention relates to adeno-associated viral (AAV) particles encoding siRNA molecules and methods for treating Huntington's Disease (HD).
Abstract: The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising an exogenous TCR and a switch receptor. Gene edited modified cells are also provided, such that the expression of one or more of an endogenous T-cell receptor gene (e.g., TRAC, TRBC) or an endogenous immune checkpoint gene (e.g., PD-1 or TIM-3) is downregulated.
Type:
Grant
Filed:
December 11, 2018
Date of Patent:
August 29, 2023
Assignee:
The Trustees of the University of Pennsylvania
Abstract: Synthetic adenoviruses having chimeric fiber proteins and liver detargeting mutations are described. The synthetic adenovirus vectors are capable of specifically infecting cells at wound sites or in regions of damaged tissue. The synthetic adenovirus vectors also are capable of expressing transgenes, such as wound healing factors, at sites of wounded or damaged tissue. Accordingly, the described vectors can be used to detect wounded or damaged tissue, and/or to promote wound healing and regeneration of damaged tissue, such as by expression of heterologous wound healing or tissue regeneration factors.
Type:
Grant
Filed:
April 4, 2018
Date of Patent:
August 22, 2023
Assignee:
Salk Institute for Biological Studies
Inventors:
Clodagh O'Shea, Colin Powers, Lei Zhang
Abstract: The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.
Type:
Grant
Filed:
July 27, 2017
Date of Patent:
August 22, 2023
Assignee:
UNIST (ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY)
Inventors:
Jeong Beom Kim, Myung Rae Park, Man Sze Wong
Abstract: The present invention provides genetic markers for identifying engraftable human cardiac ventricular progenitor cells. The engraftment markers of the invention include angiogenic markers and extracellular matrix markers. Human ventricular progenitor cells expressing these markers are capable of forming ventricular tissue in vivo that is vascularized and supported by an extracellular matrix. Methods of engrafting human cardiac ventricular progenitor cells by transplanting into a subject progenitor cells that express the engraftment markers are also provided.
Type:
Grant
Filed:
March 3, 2020
Date of Patent:
August 15, 2023
Assignee:
Procella Therapeutics AB
Inventors:
Chuen Yan Leung, Jonathan Clarke, Jiejia Xu, Federica Santoro, Makoto Sahara, Kenneth R. Chien